BioAlliance Pharma signs a co-promotion agreement with Lundbeck for in-hospital prescription of the antidepressant Seroplex®

BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announced the signature of a 2009 co-promotion agreement with Lundbeck for the latter’s Seroplex® antidepressant. BioAlliance Pharma will co-promote Seroplex® to its core healthcare partners (notably oncologists, radiotherapists and hematologists) as part of a comprehensive approach to patient management in general and cancer therapy in particular, in line with France’s national guidelines for cancer patients. Dominique Costantini, BioAlliance Pharma’s President and CEO, stated “We are clearly delighted with Lundbeck’s choice of BioAlliance Pharma as a co-promotion partner – a choice which validates the quality of our work and that of our hospital-focused sales team. With Loramyc® and now Seroplex® (which also has a role in supportive care), BioAlliance Pharma is optimizing its sales and marketing resources”.